Skip to content
AI IntelligenceFeb 23, 2026M&A
Article

HBM Pharmaceuticals -> Solstice Oncology (Lizenz für HBM4003)

HBM Pharmaceuticals (和铂医药) has entered into a licensing agreement and equity collaboration with Solstice Oncology. HBM grants exclusive development and commercialization rights for the clinical-stage antibody candidate HBM4003 outside Greater China. HBM receives $105M upfront (including equity) and is eligible for up to ~$11B in milestone payments.

AI-generated: summaries written by AI from the linked sources. How we use AI

AI-generatedSource: 36Kr
01

Source Brief

HBM Pharmaceuticals (和铂医药) has entered into a licensing agreement and equity collaboration with Solstice Oncology. HBM grants exclusive development and commercialization rights for the clinical-stage antibody candidate HBM4003 outside Greater China. HBM receives $105M upfront (including equity) and is eligible for up to ~$11B in milestone payments.

02